

**GOVERNMENT OF INDIA  
MINISTRY OF CHEMICALS AND FERTILIZERS  
DEPARTMENT OF PHARMACEUTICALS**

LOK SABHA  
UNSTARRED QUESTION No. 5597  
TO BE ANSWERED ON 04<sup>TH</sup> APRIL 2025

**Cancer Drugs**

**5597. Shri Chavan Ravindra Vasantrao:  
Shri Dhairyasheel Sambhajirao Mane:**

Will the Minister of **CHEMICALS AND FERTILIZERS** be pleased to state:

- (a) whether most cancer drugs, at present, are imported making them prohibitively expensive;
- (b) if so, the details thereof along with the corrective measures taken/being taken by the Government to reduce the import of cancer drugs in the country;
- (c) whether as per data from the ICMR, cancer burden is likely to increase in coming years in the country, and if so, the details thereof;
- (d) whether the country's drug makers are producing cancer drugs under the Production Linked Incentive (PLI) scheme;
- (e) if so, the details along with the results thereof; and
- (f) the manner in which this step of the Government will boost domestic production and strengthen the position of the country as the pharmacy of the world?

**ANSWER**

**THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS**

**(SMT. ANUPRIYA PATEL)**

(a) and (b): As per data of the Directorate General of Commercial Intelligence and Statistics for the financial year 2024-25 (till the month of December 2024), anti-cancer medicines worth US\$ 41.52 million were imported into the country. The Department is implementing the Production Linked Incentive (PLI) scheme for pharmaceuticals to increase domestic production of high-value medicines, including anti-cancer drugs.

(c): As per data of the National Cancer Registry Programme of the Indian Council of Medical Research (ICMR), the estimated number of incidence of cancer cases in the country for the year 2025 is 15,69,793. As per the Global Cancer Observatory, International Agency for Research on Cancer, the estimated number of incidence of cancer cases in India is likely to increase to 22,18,694 by the year 2040.

(d) to (f): Under the PLI Scheme for Pharmaceuticals, financial incentive is provided to 55 selected applicants for manufacturing identified products, which include anti-cancer drugs. Details regarding the anti-cancer drugs manufactured under the scheme, including the details of domestic sales and exports of such drugs during the last three years, are at Annexure.

**Annexure referred to in the reply to parts (d) to (f) of Lok Sabha Unstarred Q. No. 5597 for answer on 4.4.2025, raised by Shri Chavan Ravindra Vasantrao and Shri Dhairyasheel Sambhajirao Mane, regarding Cancer Drugs**

**Details of anti-cancer drugs being manufactured under the PLI Scheme for Pharmaceuticals**

<b>S. No.</b>	<b>Anti-cancer drug</b>	<b>Therapeutic use</b>
1	Abiraterone	Prostate cancer
2	Afatinib	Lung cancer
3	Anastrozole	Breast cancer
4	Apalutamide	Prostate cancer
5	Arsenic trioxide	Acute promyelocytic leukaemia
6	Axitinib	Advanced renal cell carcinoma
7	Azacitidine	Myelomonocytic leukaemia
8	Bendamustine	Chronic lymphocytic leukaemia
9	Bevacizumab	Colorectal, Lung and Ovarian cancer
10	Bexarotene	Cutaneous T-cell lymphoma
11	Bicalutimide	Spread of cancer Cells
12	Bleomycin	Testicular cancer
13	Bortezomib	Blood plasma cell cancer
14	Bosutinib monohydrate	Chronic myelogenous leukaemia
15	Busulphan	Chronic myelogenous leukaemia
16	Cabazitaxel	Castration-resistant prostate cancer
17	Cabozantinib	Medullary thyroid cancer
18	Capecitabine	Metastatic Breast and Colorectal Cancers
19	Capecitabine + cyclophosphamide	Metastatic colorectal cancer
20	Carboplatin	Cancer of the Ovaries
21	Carfilzomib	Multiple myeloma
22	Carmustine	Lymphomas and Brain Tumours
23	Cisplatin	Bladder, Ovarian and Testicular Cancers
24	Clofarabine	Acute lymphoblastic leukaemia
25	Cyclophosphamide	Cancer of the ovaries and breast
26	Cytarabine	Cancer of the white blood cells
27	Decitabine	Myelodysplastic syndromes
28	Docetaxel	Breast, ovarian and non-small cell lung cancer
29	Doxorubicin hydrochloride	Leukaemia and lymphoma
30	Enzalutamide	Prostate cancer
31	Epirubicin	Breast cancer
32	Eribulin	Metastatic breast cancer
33	Erlotinib hydrochloride	Lung cancer and pancreatic cancer
34	Etoposide	Various cancers such as testicular, prostate, bladder, stomach and lung
35	Everolimus	Renal cell cancer and other tumours

36	Exemestane	Breast cancer
37	Fluorouracil	Breast cancer
38	Fulvestrant	Breast cancer
39	Gefitinib	Breast, lung and other cancers
40	Gemcitabine	Pancreatic, breast, lung and ovarian cancers
41	Ibrutinib	Chronic lymphocytic leukaemia
42	Imatinib	Chronic myelogenous leukaemia
43	Imiquimod	Basal cell carcinoma
44	Irinotecan	Colon cancer and small cell lung cancer
45	Lenalidomide	Multiple myeloma, myelodysplastic syndromes
46	Lenvatinib	Progressive, differentiated thyroid cancer
47	Letrozole	Breast cancer
48	Leuprolide acetate	Prostate cancer
49	Melphalan	Multiple myeloma
50	Methotrexate	Breast, head and neck, lung and blood cancer
51	Midostaurin	Acute myeloid leukaemia
52	Nano paclitaxel	Breast, lung and pancreatic cancer
53	Nelarabine	T-cell acute lymphoblastic leukaemia
54	Nilotinib	Chronic myeloid leukaemia
55	Nimotuzumab	Head and neck cancer and cancer of colon and rectum
56	Olaparib	Ovarian cancer and fallopian tube cancer
57	Oxaliplatin	Colon or rectal cancer
58	Paclitaxel	Breast, ovarian and lung cancer
59	Palbociclib	Metastatic breast cancer
60	Pazopanib	Advanced renal cell carcinoma
61	Pegaspargase	Acute lymphoblastic leukaemia
62	Peglypodoxorubicin	Ovarian cancer and Kaposi sarcoma
63	Pemetrexed	Metastatic non-squamous non-small cell lung cancer
64	Rituximab	Non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
65	Sorafenib tosylate	Kidney cancer
66	Sunitinib	Renal cell carcinoma
67	Tamoxifen citrate	Breast cancer
68	Temozolomide	Brain tumours
69	Thiotepa	Breast, ovarian and bladder cancer
70	Topotecan hydrochloride	Ovarian, lung and cervical cancer
71	Toremifene citrate	Breast cancer
72	Trabectidine	Advanced soft-tissue sarcoma
73	Trastuzumab	Breast and stomach cancer
74	Venetoclax	Chronic lymphocytic leukaemia
75	Vinorelbine tartrate	Non-small cell lung cancer and breast cancer

**Sales and exports of anti-cancer drugs manufactured under the PLI Scheme for  
Pharmaceuticals**

<b>Financial year</b>	<b>Domestic sales (in crore ₹)</b>	<b>Export sales (in crore ₹)</b>	<b>Total sales (in crore ₹)</b>
2022-23	1,402.58	9,373.7	10,776.28
2023-24	1,776.24	13,258.65	15,034.89
2024-25 (till December 2024)	1,521.48	11,602.29	13,123.77

\*\*\*\*\*